Market Cap | 1.04B | P/E | - | EPS this Y | 4.10% | Ern Qtrly Grth | - |
Income | -227.04M | Forward P/E | -6.08 | EPS next Y | 0.90% | 50D Avg Chg | 3.00% |
Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | 3.00% |
Dividend | N/A | Price/Book | 5.51 | EPS next 5Y | - | 52W High Chg | -31.00% |
Recommedations | 1.80 | Quick Ratio | 9.08 | Shares Outstanding | 109.45M | 52W Low Chg | 30.00% |
Insider Own | 0.13% | ROA | -37.18% | Shares Float | 70.23M | Beta | 0.03 |
Inst Own | 112.37% | ROE | -62.92% | Shares Shorted/Prior | 9.73M/10.23M | Price | 12.52 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 692,954 | Target Price | 16.40 |
Oper. Margin | - | Earnings Date | Oct 31 | Volume | 817,742 | Change | -6.15% |
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.
Citigroup | Buy | Sep 24, 24 |
Baird | Neutral | Sep 5, 24 |
HC Wainwright & Co. | Buy | Sep 3, 24 |
JP Morgan | Overweight | Aug 7, 24 |
Needham | Buy | Aug 7, 24 |
Needham | Buy | Jun 27, 24 |
HC Wainwright & Co. | Buy | Jun 17, 24 |
Needham | Buy | Jun 17, 24 |
Wedbush | Neutral | May 24, 24 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Fairmount Funds Management LLC | - - | Jun 16 | Buy | 8.25 | 1,200,000 | 9,900,000 | 2,472,124 | 06/21/22 |